29 October 2024

Held on Tuesday, October 29, 2024 at 15:00 GMT / 16:00 CET / 11:00 EDT / 8:00 PDT

What's the webinar about?

Join experts from IIT (Italian Institute of Technology) and Medix Biochemica as they showcase a new lyophilized LAMP solution and how it can be used for applications ranging from Real-Time SNP Genotyping to Infectious Disease Testing.
Expect to learn about:

  • The role of LAMP in point-of-need testing 

  • How this new lyophilized solution has already been used to detect a wide range of micro-organisms, such as Mycobacterium tuberculosis and Salmonella enterica 

  • How running Double-Tube LAMP can be used as part of a food fraud detection panel 

  • Workflows for Real-Time SNP Genotyping and Infectious Disease Testing

This webinar is perfectly suited for researchers, healthcare practitioners, lab staff, and anyone keen on the latest developments in medical diagnostics. 

LAMP Webinar Slides Image
Watch on YouTube Download the Slide Deck

If you've watched our webinar then please let us know how we did

Take Our Survey Now

Contact us for questions or any feedback at mdx@medixbiochemica.com or click the button below:

Webinar Q&A:

  1. How does the operator's ability to interpret Lyo-LAMP results impact the overall effectiveness of the test?
    The test has been designed to be user-friendly in every aspect, including the interpretation of results. Thanks to its design, interpreting the results is made as simple and intuitive as possible. For example, in microorganism detection, the results are binary (on-off), indicating the presence or absence of a curve. This means that if the microorganism is present, a curve will be visible; if not, there will be no curve. It’s as clear as a yes or no answer. In SNPs, interpretation involves simply observing which curve is faster, making the interpretation quick and easy. This design ensures that even those with minimal technical expertise can accurately interpret the results, enhancing the test’s overall usability and effectiveness.
  2. After COVID-19, the use of LAMP has increased, but why are there not many commercial kits available?
    The difficulty in integrating LAMP techniques into standard routines fundamentally depends on two factors. The first one is the acceptance of a different technique than the PCR, widely regarded as the gold standard in molecular diagnostics. There is a significant challenge in getting the scientific and medical communities to accept a different technique like LAMP, which, despite its advantages, is still seen as a less performant alternative. The second factor is that developing LAMP assays that can truly compete with PCR is challenging. These factors contribute to the slower adoption of LAMP techniques in routine diagnostic practices.
  3. Can the Lyo-LAMP beads be applied to a 96 well-plate or to other formats?
    The design of Lyo-LAMP beads is tailored for versatility, making them ideal for both point-of-care (POC) testing and high-throughput applications. The beads can be easily sorted directly into 96-well plates, streamlining the workflow. To further enhance flexibility, we offer a 96-well plate format with breakaway capabilities, allowing users to customize their setup based on specific needs. Additionally, the Lyo-LAMP beads can be used with various tube sizes and formats, such as PCR strips or individual tubes. For even greater customization, we can adjust the bead size upon request.
  4. To what extent can colorimetric detection be effectively utilized in your applications, and what are the potential benefits and limitations associated with its use?
    Colorimetric detection can be effectively used in LAMP applications, offering both benefits and limitations. We have also developed LAMP-based tests with a colorimetric readout. This type of detection involves reading a color change by the naked eye. In certain applications, this detection method can be advantageous as it further simplifies the necessary instrumentation, making it ideal for low resource settings, for example.
    However, compared to a fluorescence-based reading, colorimetric detection is less sensitive, takes more time, and requires very precise optimization of the color shift, to ensure the color change is objective, with a user-independent test readout.
  5. How stable and resistant to humidity is a Lyo-LAMP?
    The current Lyo-LAMP prototype is still under evaluation, but it has already demonstrated good stability in preliminary tests conducted by IIT. Typically, our off-the-shelf Lyobeads, which include a master mix in a 96-well plate format, maintain stability for up to 2 years when properly sealed. To further improve their performance, we are developing a protocol to enhance their humidity resistance, aiming to minimize risks related to improper transportation or storage. This advancement will also simplify handling for end-users, particularly when transferring lyobeads received in bulk into new tubes or devices like microchips. Humidity-resistant lyobeads will reduce the need for a humidity-controlled environment, making the workflow more cost-effective and efficient.
  6. I guess this technology is not suitable for home testing. Will it be one day?
    In the future, Lyo-LAMP could be adapted for home testing in a further simplified format, as it is not bound to a specific platform. If we collaborate with companies developing compact, home-use devices, this technology could easily integrate with such devices for user-friendly, at-home applications. Currently, our tests are designed to be performed outside of a laboratory setting, making them suitable for use in places like pharmacies or doctor’s offices. This is made possible by Lyo-LAMP’s simplified procedures and the availability of portable, affordable instruments for running the tests.
  7. What is the frequency of its qualification?
    We apologies but we did not fully understand your question, please feel free to contact us directly mdx@medixbiochemica.com to get an answer.
  8. Could you provide more details on the DNA extraction step? Can it work at temps below 95°C?
    Currently, we use a 5-minute thermochemical extraction at 95°C to minimize time-to-result and reduce sample matrix interferences. However, we can also develop a custom room-temperature extraction step if needed, as we have successfully implemented room-temperature protocols in the past.
  9. How do you get around the non-specific amplification - we have found this to be the most problematic.  I know that primer design is key but we are using published primer LAMP sets that we have shown the non-specific binding to be an issue - how are others getting around this?
    Our experience has shown that replicating published LAMP protocols and using pre-existing LAMP primers often yields results that differ significantly from those reported in the original studies. In 99% of cases, false positives—aside from those due to cross-contamination—result from primer non-specificity, and it is typically impossible to improve the specificity of a reaction using non-specific primers. However, thanks to our extensive expertise in reaction design, we have optimized our LAMP reactions to avoid non-specific amplification entirely. Therefore, we have never encountered this issue in our work.
  10. What will be the cost compare to qPCR?
    The overall cost of Lyo-LAMP is generally lower than that of PCR-based tests. While lyophilized Lyo-LAMP beads may be more expensive than liquid PCR reagents, they are still more affordable than lyophilized PCR reagents. Additionally, LAMP requires less costly equipment—often a fraction of the price of a thermal cycler—and can be operated by less specialized staff, reducing costs associated with training and minimizing the risk of cross-contamination. Furthermore, the faster turnaround time of LAMP increases the number of reactions that can be performed daily, boosting throughput and revenue potential compared to PCR.
  11. Can you inform us for pharma applications?
    The pharmaceutical field offers exciting opportunities for innovation, and LAMP technology can play a significant role in advancing diagnostic and therapeutic solutions. For instance, we have already developed specialized tests for pharmacogenetic applications, enabling more personalized approaches to drug therapy by analyzing genetic factors that influence individual responses to medications.
    However, the potential applications extend far beyond pharmacogenetics. We can collaborate to explore new targets aligned with your specific goals—whether that means developing rapid, point-of-care diagnostic tools, optimizing drug development pipelines, or identifying biomarkers for novel therapies. With LAMP’s flexibility, affordability, and rapid turnaround, it can be a powerful tool in expanding precision medicine and enhancing the efficiency of pharmaceutical research and development.

Our speakers and host for the webinar

Dr. Paola Cecere Profile Image Large
Dr. Paola Cecere
Postdoctoral Researcher, Istituto Italiano di Tecnologia (IIT)
Dr. Pier Paolo Pompa
Dr. Pier Paolo Pompa
Research Director and Head of the Nanobiointeractions & Nanodiagnostics Labs of Istituto Italiano di Tecnologia (IIT)
Dr. Giuseppina Sannino
Dr. Giuseppina Sannino
Global Business Development Manager MDx, Medix Biochemica
Anthony Austin
Anthony Austin
Global Marketing Manager, Medix Biochemica

 

If you would like to subscribe to future Medix Biochemica events simply click the link below.

Subscribe to Future Events

Speaker Bio's

Dr. Paola Cecere

Paola Cecere obtained her M.Sc. in “Medicinal Chemistry and Pharmaceutical Technology” at the University of Bari. In 2013, she worked as a research fellow at the Center for Biomolecular Nanotechnologies (CBN) of IIT (Lecce), where, in 2014, she started her PhD in “Materials Science and Structural Engineering and Nanotechnologies.” Since 2015, she moved to the Central Research Labs of IIT in Genova, where she completed her PhD course and worked as a postdoctoral researcher from 2017 to 2020. From 2021 to 2023, she was the technical manager for MC Biotech srl, a start-up company in Sesto Calende (Lombardia), in the field of molecular diagnostics for human and veterinary applications. Since May 2023, she has been a postdoctoral researcher in the Nanobiointeractions & Nanodiagnostics Labs at Istituto Italiano di Tecnologia (IIT) in Genoa.

Her research is focused on the design and development of colorimetric and fluorescence-based diagnostic strategies, based on enzymatic or target/signal isothermal amplification reactions (such as LAMP), for point-of-care applications for human health and wellness, as well as food safety and traceability.

 

Dr. Pier Paolo Pompa

After his degree in Physics in 2005, Pier Paolo took a PhD in Nanoscience at the National Nanotechnology Laboratory (NNL) in Lecce. PPP subsequently joined NNL as a junior researcher and, since 2008, as a staff scientist. In 2009, he moved to the Center for Biomolecular Nanotechnologies (CBN) of IIT, where he was first appointed Coordinator of the Environment, Health and Safety (EHS) Research Platform and, in 2011, Director of CBN. In 2015, he moved to the Central Research Labs of IIT in Genova. He is also a Contract Professor at the University of Genova (Department of Biotechnology), a Member of the University Board for the PhD School (Department of Chemistry), an Editorial Board Member of several international journals, and a Member of the Scientific Committee of several international conferences.


His scientific activities are highly interdisciplinary, ranging from nanotechnology to biophysics, nanodiagnostics, nanomedicine, nanobiotechnology, and nanochemistry, and are intensively focused on the understanding of the interaction between nanomaterials and living systems and the development of low-cost hybrid sensing strategies, based on nanoparticles, for point-of-care diagnostics.


PPP has authored over 200 peer-reviewed publications in international journals (including Nature Nanotech, PNAS, Nature Comm, ACS Nano, Angew Chem, Adv Mater, and Chem Soc Rev, with >13,500 citations), several book chapters, and many invited and oral contributions to international conferences. He is also the author of over 35 international patents. He has led various national and international projects in the field of nanobiotechnology (>7.1 M€ of competitive grants). He is also a reviewer for major scientific journals (Nature Mater, Nature Nanotech, etc.) and international funding agencies (ISF, ACS, HFSP).

 

Dr. Giuseppina Sannino

Giuseppina is an accomplished professional in the area of molecular biology and serves as the Global Business Development Manager for Medix Biochemica’s MDx business. After achieving her PhD in Cancer Biology from the University of Tübingen, Giuseppina worked at MicroGEM, a novel nucleic acid extraction reagent manufacturer as Head of Business and Application Development (EMEA), before making the move to Medix Biochemica. Originally from Italy, Giuseppina is now based in Germany, and uses her impressive scientific background, in combination with her business knowledge, to spearhead the creation of strategic partnerships, along with driving business development and sales strategies on an international scale. Her focus encompasses Medix Biochemica's unique polymerases and suite of custom services.

 

Anthony Austin

Anthony is the Global Marketing Manager for Medix Biochemica, starting in 2022. He enters this role after 15 years holding various science focused responsibilities in R&D, Manufacturing, Analytical and Product Management. Prior to Medix Biochemica, he worked in academic labs studying bone metabolism and genetic diseases affecting white blood cells and their ability to fight infections.